Business Wire

TX-SNOW-SOFTWARE

16.11.2023 15:01:58 CET | Business Wire | Press release

Share
Snow Software Unveils Snow Copilot, its First Generative AI Assistant, Built to Solve Large Challenges in IT Asset Management and FinOps

Snow Software, the global leader in technology intelligence, today previewed Snow Copilot, the first-in-a-series of Artificial Intelligence (AI) capabilities designed to solve large challenges in IT Asset Management (ITAM) and FinOps. Developed in its innovation incubator Snow Labs, Snow Copilot is an AI assistant that empowers users to ask conversational questions and receive natural language responses. At release, Snow Copilot is available for Software Asset Management (SAM) computer data in Snow Atlas with more use cases being explored over time.

Snow Labs is a multiprong innovation initiative to help organizations make better decisions and deliver positive business outcomes with Technology Intelligence, or the ability to understand and manage all technology data, via Snow Atlas. The current project focuses on using artificial intelligence to advance data insights and further explore ways to tackle multifaceted ITAM and FinOps challenges, the first offering powered by Snow AI.

“We created Snow Labs as a space for rapid experimentation and prototyping, allowing us to test emerging technologies that sat outside of our standard product roadmap,” said Steve Tait, Chief Technology Officer and EVP, Research and Development at Snow. “Artificial intelligence is a great example of a rapidly evolving, emerging technology that could allow Snow Labs to address a myriad of challenges our customers face when making sense of their technology asset data. We believe that AI will fundamentally transform the way our customers and partners interact with their data. This is just one of many ways we are working to bring our vision around Technology Intelligence to life through innovation.”

Enhancing the Value of Data with Snow

IT manages vast amounts of data but struggles to turn that data into actionable intelligence for business impact. According to a recent Snow report, 91% of IT leaders said they need to invest in tools to extract more value out of their data. This is a contributing factor in the growing visibility gap between IT and the business units they support. IT struggles to know what software and cloud services are running both within IT and across the enterprise leading to technology overspend, higher security and compliance risk, reduced ITSM data quality, and slower decision-making. Generative AI provides new toolsets for Snow to tackle the visibility gap when it comes to understanding and acting on large technology asset data sets for ITAM, SaaS management, and FinOps.

Snow Copilot, one of the first AI assistants developed to solve advanced challenges for ITAM and FinOps, leverages the Microsoft Azure OpenAI Service. It allows customers to input questions and receive insights on their computer data, such as “How many computers have been installed in the last 90 days?,” as well as explore “what if” scenarios all directly within Snow Atlas. Snow Copilot reduces the need to export data into PowerBI or Excel to get insights into advanced questions on forecasting, asset allocation, and trend identification of SAM computer data. All data remains secure in the customer environment ensuring data privacy and integrity.

Additional AI-enabled features within the Snow AI umbrella are under exploration for 2024, including:

  • Machine Learning Entitlement Ingestion: Eliminate manual, costly entitlement uploads with automated invoice processing powered by machine learning.
  • Enhanced Data Intelligence Service (DIS) dataset with OpenAI: Receive more context about the SaaS applications running in your organization with enhanced descriptions including richer details on categories, function, etc. from the Snow DIS normalization and augmentation service.
  • Fine-tuning Large Language Models (LLM) on Snow proprietary data: Make more informed and complex decisions on technology assets with personalized licensing recommendations.

These new AI capabilities will be available on Snow Atlas, the company’s Technology Intelligence platform. The platform, released in 2021, provides a more flexible and scalable foundation for continuous innovation. Snow Atlas allows organizations to bring together their ITAM, SaaS management, cloud cost and FinOps functions, providing a unified view and actionable intelligence to manage the entire IT landscape.

“The pace at which we can innovate on Snow Atlas, both in our standard product development cycles and through Snow Labs, is remarkable with more than one production release every day for the last three quarters,” said Tait. “We are entering a new era which will redefine how we work with technology, and we want to ensure organizations feel confident and prepared to embrace this monumental shift.”

Snow Copilot and other AI innovations will be available for current Snow Atlas customers who apply for the beta program. To learn more about Snow Labs and its innovation agenda, read CTO Steve Tait’s latest blog or to discover more on Snow Atlas, visit: https://www.snowsoftware.com/products/snow-atlas/.

About Snow Software

Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116093425/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye